These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 22277196)

  • 41. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.
    Mitra AP; Bartsch CC; Bartsch G; Miranda G; Skinner EC; Daneshmand S
    Urol Oncol; 2014 Feb; 32(2):117-27. PubMed ID: 23477878
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Commentary on "Detection and oncological effect of circulating tumor cells in patients with variant urothelial carcinoma histology treated with radical cystectomy.".
    Soave A; Riethdorf S; Dahlem R; Minner S; Weisbach L; Engel O; Fisch M; Pantel K; Rink M
    Urol Oncol; 2018 Jul; 36(7):347-348. PubMed ID: 29880457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy.
    Wright JL; Lin DW; Porter MP
    Cancer; 2008 Jun; 112(11):2401-8. PubMed ID: 18383515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk factors and outcomes of urethral recurrence following radical cystectomy.
    Boorjian SA; Kim SP; Weight CJ; Cheville JC; Thapa P; Frank I
    Eur Urol; 2011 Dec; 60(6):1266-72. PubMed ID: 21871713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.
    Wülfing P; Borchard J; Buerger H; Heidl S; Zänker KS; Kiesel L; Brandt B
    Clin Cancer Res; 2006 Mar; 12(6):1715-20. PubMed ID: 16551854
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor.
    Fleischmann A; Thalmann GN; Markwalder R; Studer UE
    J Clin Oncol; 2005 Apr; 23(10):2358-65. PubMed ID: 15800327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
    Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN
    Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
    Chromecki TF; Cha EK; Fajkovic H; Rink M; Ehdaie B; Svatek RS; Karakiewicz PI; Lotan Y; Tilki D; Bastian PJ; Daneshmand S; Kassouf W; Durand M; Novara G; Fritsche HM; Burger M; Izawa JI; Brisuda A; Babjuk M; Pummer K; Shariat SF
    BJU Int; 2013 Feb; 111(2):249-55. PubMed ID: 22727036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gender-specific outcomes of bladder cancer patients: a stage-specific analysis in a contemporary, homogenous radical cystectomy cohort.
    Soave A; Dahlem R; Hansen J; Weisbach L; Minner S; Engel O; Kluth LA; Chun FK; Shariat SF; Fisch M; Rink M
    Eur J Surg Oncol; 2015 Mar; 41(3):368-77. PubMed ID: 24674298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.
    Fajkovic H; Cha EK; Jeldres C; Donner G; Chromecki TF; Margulis V; Novara G; Lotan Y; Raman JD; Kassouf W; Seitz C; Bensalah K; Weizer A; Kikuchi E; Roscigno M; Remzi M; Matsumoto K; Breinl E; Pycha A; Ficarra V; Montorsi F; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2012 Mar; 187(3):845-51. PubMed ID: 22248522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy.
    Linder BJ; Frank I; Cheville JC; Tollefson MK; Thompson RH; Tarrell RF; Thapa P; Boorjian SA
    Eur Urol; 2013 May; 63(5):839-45. PubMed ID: 23332883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.
    Munzone E; Nolé F; Goldhirsch A; Botteri E; Esposito A; Zorzino L; Curigliano G; Minchella I; Adamoli L; Cassatella MC; Casadio C; Sandri MT
    Clin Breast Cancer; 2010 Oct; 10(5):392-7. PubMed ID: 20920984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
    Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
    J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS; Tzai TS; Chow NH
    Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
    Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
    J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
    Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
    Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research.
    Skagias L; Politi E; Karameris A; Sambaziotis D; Archondakis A; Vasou O; Ntinis A; Michalopoulou F; Moreas I; Koutselini H; Patsouris E
    J BUON; 2009; 14(3):457-62. PubMed ID: 19810139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.